cas 1773508-16-9|| where to buy (1s,3s)-3-(Trifluoromethoxy)cyclobutanecarboxylic acid

Nom du produit:(1s,3s)-3-(Trifluoromethoxy)cyclobutanecarboxylic acid

IUPAC Name:(1s,3s)-3-(trifluoromethoxy)cyclobutane-1-carboxylic acid

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM1047784-250mg	in stock	ƿȯƛ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1773508-16-9 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1773508-16-9; Formule moléculaire:C6H7F3O3; Point de fusion:-; Code SMILES:O=C([C@H]1C[C@@H](OC(F)(F)F)C1)O; Densité:

: Numéro de catalogue:CM1047784; Poids moléculaire:184.11; Point d'ébullition:; N° Mdl:; Stockage:

: Cyclobutanes; The molecular structure of cyclobutane has four carbon atoms, and its four carbon atoms are not in the same plane, which is the folded conformation of cyclobutane. Cyclobutane itself is not of commercial or biological interest, but more complex derivatives are important in biology and biotechnology. Currently, nine FDA-approved drugs contain the cyclobutane structure. From the perspective of therapeutic areas, cyclobutyl drugs are mainly distributed in popular areas such as tumors, neurological diseases, infectious diseases, endocrine and metabolic diseases.

: DNL343; Denali Therapeutics announces completion of enrollment for regimen G evaluating eIF2B agonist DNL343 in the phase 2/3 HEALEY ALS platform trial. Amyotrophic lateral sclerosis (ALS) causes progressive nerve degeneration in the spinal cord and brain, representing a large unmet medical need. The activation of integrated stress response (ISR) is documented in ALS patients, resulting in the suppression of eukaryotic translation initiation factor 2B (eIF2B) activity, and impaired protein synthesis.
Denali's ALS therapy DNL343 is an investigational small molecule eIF2B activator. It is designed to restore protein synthesis and inhibit ISR pathway in ALS. The compound is found to be generally well-tolerated and support once-daily dosing.